Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a Single Institution

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 2, 2015, Pages 326-334

  Garfin, Phillip M ^a   Link, Michael P ^a   Donaldson, Sarah S ^a   Advani, Ranjana H ^a   Luna Fineman, Sandra ^a   Kharbanda, Sandhya ^a   Porteus, Matthew ^a   Weinberg, Kenneth I ^a   Agarwal Hashmi, Rajni ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous transplantation; Hodgkin lymphoma; Outcome; Pediatric

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; GEMCITABINE; LOMUSTINE; NAVELBINE; MYELOABLATIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; GAMMA RADIATION; GRAFT VS HOST DISEASE; IMMUNOLOGY; MORTALITY; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; THERAPEUTIC USE; TRANSPLANTATION CONDITIONING; TUMOR RECURRENCE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CARMUSTINE; CHILD; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; GAMMA RAYS; GRAFT VS HOST DISEASE; HODGKIN DISEASE; HUMANS; MALE; MYELOABLATIVE AGONISTS; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84920901898     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.020     Document Type: Article

References (32)

1. Bazzeh F., Rihani R., Howard S., Sultan I. Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases. Leuk Lymphoma 2010, 51:2198-2207.
2. Kelly K.M., Hodgson D., Appel B., et al. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 2013, 60:972-978.
3. Friedmann A.M., Wolfson J.A., Hudson M.M., et al. Relapse after treatment of pediatric hodgkin lymphoma: outcome and role of surveillance after end of therapy. Pediatr Blood Cancer 2013, 60:1458-1463.
4. Hudson M.M., Donaldson S.S. Treatment of pediatric Hodgkin's lymphoma. Semin Hematol 1999, 36:313-323.
5. Yuen A.R., Rosenberg S.A., Hoppe R.T., et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997, 89:814-822.
6. Claviez A., Sureda A., Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 2008, 42(Suppl 2):S16-S24.
7. Olson M.R., Donaldson S.S. Treatment of pediatric hodgkin lymphoma. Curr Treat Options Oncol 2008, 9:81-94.
8. Vassilakopoulos T.P., Angelopoulou M.K. Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years. Semin Hematol 2013, 50:4-14.
9. Schmitz N., Buske C., Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol 2007, 44:234-245.
10. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359:2065-2071.
11. Baker K.S., Gordon B.G., Gross T.G., et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. JClin Oncol 1999, 17:825-831.
12. Cairo M.S., Woessmann W., Pagel J. Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas. Biol Blood Marrow Transplant 2013, 19:S38-S43.
13. Frankovich J., Donaldson S.S., Lee Y., et al. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 2001, 7:49-57.
14. Lieskovsky Y.E., Donaldson S.S., Torres M.A., et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. JClin Oncol 2004, 22:4532-4540.
15. William B.M., Loberiza F.R., Whalen V., et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2013, 13:417-423.
16. Phillips G.L., Wolff S.N., Herzig R.H., et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989, 73:2086-2092.
17. Radford J.A., Cowan R.A., Flanagan M., et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol. 1986, 6(6):940-946.
18. Horning S.J. Primary refractory Hodgkin's disease. Ann Oncol 1998, 9(Suppl 5):S97-S101.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
20. Harris P.A., Taylor R., Thielke R., et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. JBiomed Inform 2009, 42:377-381.
21. Moskowitz C.H., Matasar M.J., Zelenetz A.D., et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012, 119:1665-1670.
22. Castellino S.M., Geiger A.M., Mertens A.C., et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011, 117:1806-1816.
23. Bayraktar U.D., Bashir Q., Qazilbash M., et al. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:344-356.
24. Morandi P., Ruffini P.A., Benvenuto G.M., et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005, 35:323-334.
25. Strobel E.S., Bauchmuller K., Ihorst G., Engelhardt M. Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature. Leuk Lymphoma 2007, 48:2255-2260.
26. Gobbi P.G., Ferreri A.J., Ponzoni M., Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol 2013, 85:216-237.
27. Nieto Y., Popat U., Anderlini P., et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013, 19:410-417.
28. Paulino A.C., Margolin J., Dreyer Z., et al. Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2012, 58:860-864.
29. Carella A.M., Bellei M., Brice P., et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. Haematologica 2009, 94:146-148.
30. Arai S., Fanale M., DeVos S., et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013, 54:2531-2533.
31. Batlevi C.L., Younes A. Novel therapy for Hodgkin lymphoma. Blood 2013, 122:394-399.
32. Garciaz S., Coso D., Peyrade F., et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol 2013, [Epub ahead of print]. 10.1002/hon. 2119.